^
    almost2years
    A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors (clinicaltrials.gov)
    P1/2, N=27, Completed, Codiak BioSciences | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    exoSTING
    2years
    A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, Codiak BioSciences | Recruiting --> Active, not recruiting | N=180 --> 27 | Trial primary completion date: Dec 2022 --> Aug 2022
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    exoSTING
    almost3years
    A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors (clinicaltrials.gov)
    P1/2, N=180, Recruiting, Codiak BioSciences | Trial primary completion date: Nov 2021 --> Dec 2022
    Clinical • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    exoSTING
    4years
    A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors (clinicaltrials.gov)
    P1/2, N=180, Recruiting, Codiak BioSciences
    Clinical • New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    exoSTING